Status:
COMPLETED
Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma
Lead Sponsor:
Sohag University
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
30-70 years
Brief Summary
detection of Survivin expression in renal cell carcinoma and correlate this expression to tumor grade and stage.
Detailed Description
renal cell carcinoma is the third most prevalent malignant tumor of the genitourinary system. deregulation of apoptosis is involved in carcinogenesis by abnormally prolonged cell survival, facilitatin...
Eligibility Criteria
Inclusion
- patients suffer from renal cell carcinomas
Exclusion
- patients received pre-operative chemotherapy or radiotherapy. patients with insufficient clinical data.
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04873180
Start Date
January 1 2020
End Date
December 30 2020
Last Update
May 7 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maisa Hashem Mohammed
Sohag, Egypt, 82524